Table of Contents Author Guidelines Submit a Manuscript
Interdisciplinary Perspectives on Infectious Diseases
Volume 2013, Article ID 839456, 8 pages
http://dx.doi.org/10.1155/2013/839456
Clinical Study

Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations

1Department of Pharmacy Practice, Shenandoah University, 1775 North Sector Court, Winchester, VA 22601, USA
2Department of Pharmacy, Winchester Medical Center, 1840 Amherst Street, Winchester, VA 22601, USA
3Department of Biopharmaceutical Sciences, Shenandoah University, 1775 North Sector Court, Winchester, VA 22601, USA

Received 24 July 2013; Accepted 6 August 2013

Academic Editor: Dino Vaira

Copyright © 2013 Amber R. Wesner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Vancomycin. Clinical Pharmacology 2000, Gold Standard Multimedia, 2010.
  2. M. J. Rybak, B. Lomaestro, J. C. Rotschafer et al., “Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” American Journal of Health-System Pharmacy, vol. 66, no. 1, pp. 82–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. E. Geraci, “Vancomycin,” Mayo Clinic Proceedings, vol. 52, no. 10, pp. 631–634, 1977. View at Google Scholar · View at Scopus
  4. C. Liu and H. F. Chambers, “Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 10, pp. 3040–3045, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. G. R. Matzke, R. W. McGory, C. E. Halstenson, and W. F. Keane, “Pharmacokinetics of vancomycin in patients with various degrees of renal function,” Antimicrobial Agents and Chemotherapy, vol. 25, no. 4, pp. 433–437, 1984. View at Google Scholar · View at Scopus
  6. R. C. Moellering Jr., D. J. Krogstad, and D. J. Greenblatt, “Vancomycin therapy in patients with impaired renal function: a nomogram for dosage,” Annals of Internal Medicine, vol. 94, no. 3, pp. 343–346, 1981. View at Google Scholar · View at Scopus
  7. J. C. Rotschafer, K. Crossley, D. E. Zaske et al., “Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations,” Antimicrobial Agents and Chemotherapy, vol. 22, no. 3, pp. 391–394, 1982. View at Google Scholar · View at Scopus
  8. K. D. Lake and C. D. Peterson, “A simplified dosing method for initiating vancomycin therapy,” Pharmacotherapy, vol. 5, no. 6, pp. 340–344, 1985. View at Google Scholar · View at Scopus
  9. H. E. Nielsen, H. E. Hansen, B. Korsager, and P. E. Skov, “Renal excretion of vancomycin in kidney disease,” Acta Medica Scandinavica, vol. 197, no. 4, pp. 261–264, 1975. View at Google Scholar · View at Scopus
  10. R. Kullar, S. N. Leonard, S. L. Davis et al., “Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines,” Pharmacotherapy, vol. 31, no. 5, pp. 441–448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Devabhakthumi, J. P. Gonzales, A. L. Tata et al., “Evaluation of vancomycin dosing and monitoring in adult medicine patients,” Hospital Pharmacy, vol. 47, no. 6, pp. 451–459, 2012. View at Publisher · View at Google Scholar
  12. R. Thalakada, M. Legal, T. T. Y. Lau, T. Luey, J. Batterink, and M. H. H. Ensom, “Development and validation of a novel vancomycin dosing nomogram for achieving high-target trough levels at 2 Canadian teaching hospitals,” The Canadian Journal of Hospital Pharmacy, vol. 65, no. 3, pp. 180–187, 2012. View at Publisher · View at Google Scholar